Arrowhead out-licenses hepatitis B candidate in deal worth as much as $3.7 billion

4 October 2018
2019_biotech_test_vial_discovery_big

Arrowhead Pharmaceuticals (Nasdaq: ARWR) saw its shares surge 19% to a high of $20.31 pre-market but plunge 15.7% to $16.04 by late morning New York trading, despite announcing a licensing deal that could earn it as much as $3.7 billion.

The company entered into a license and collaboration agreement with Janssen Pharmaceuticals, a part of healthcare giant Johnson & Johnson (NYSE: JNJ), to develop and commercialize ARO-HBV, which has potential as chronic hepatitis B virus (HBV) treatment.

In addition, Arrowhead entered into a research collaboration and option agreement with Janssen to potentially collaborate for up to three additional RNA interference (RNAi) therapeutics against new targets to be selected by Janssen. The transactions have a combined potential value of over $3.7 billion for Arrowhead.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology